Avalon Globocare (OTCMKTS:AVCO) versus Genpact (OTCMKTS:G) Financial Comparison

Genpact (NYSE:G) and Avalon Globocare (OTCMKTS:AVCO) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Risk & Volatility

Genpact has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Avalon Globocare has a beta of -2.03, suggesting that its stock price is 303% less volatile than the S&P 500.

Valuation & Earnings

This table compares Genpact and Avalon Globocare’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genpact $3.00 billion 2.45 $282.02 million $1.60 24.11
Avalon Globocare $1.08 million 139.44 -$3.46 million N/A N/A

Genpact has higher revenue and earnings than Avalon Globocare.


This table compares Genpact and Avalon Globocare’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genpact 8.91% 22.33% 8.64%
Avalon Globocare -365.09% -81.16% -44.88%


Genpact pays an annual dividend of $0.34 per share and has a dividend yield of 0.9%. Avalon Globocare does not pay a dividend. Genpact pays out 21.3% of its earnings in the form of a dividend.

Institutional & Insider Ownership

94.0% of Genpact shares are owned by institutional investors. 1.9% of Genpact shares are owned by company insiders. Comparatively, 75.0% of Avalon Globocare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Genpact and Avalon Globocare, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genpact 0 2 7 0 2.78
Avalon Globocare 0 0 0 0 N/A

Genpact currently has a consensus price target of $34.47, indicating a potential downside of 10.66%. Given Genpact’s higher probable upside, equities research analysts plainly believe Genpact is more favorable than Avalon Globocare.


Genpact beats Avalon Globocare on 10 of the 13 factors compared between the two stocks.

About Genpact

Genpact Limited provides business process outsourcing and information technology (IT) services North and Latin America, India, rest of Asia, and Europe. Its finance and accounting services include accounts payable, such as document management, invoice processing, approval and resolution management, and travel and expense processing; invoice-to-cash services, including customer master data management, credit and contract management, fulfillment, billing, collections, and dispute management services; record to report services comprising accounting, treasury, tax, product cost accounting, and closing and reporting services; enterprise performance management consisting of budgeting, forecasting, and business performance reporting; and enterprise risk and compliance services, including operational risks and controls. It also provides transformation services; core industry operation services; and sourcing and procurement services, such as direct and indirect strategic sourcing, category management, spend analytics, procurement operations, master data management, and other procurement and supply chain advisory services. In addition, the company's IT services comprise end-user computing support, infrastructure management, application production support, and database management services, as well as business intelligence and data, enterprise resource planning, quality assurance, technology integration, and business intelligence reporting services. It serves banking and financial services, capital markets, insurance, consumer product goods and retail, life sciences and healthcare, infrastructure, manufacturing and services, insurance, and high-tech industries. Genpact Limited was founded in 1997 and is based in Hamilton, Bermuda.

About Avalon Globocare

Avalon GloboCare Corp., together with its subsidiaries, engages in integrating and managing healthcare services and resources in the United States. It provides medical related consulting services and develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology, as well as rehabilitation medicine. The company also develops proprietary diagnostic and therapeutic products leveraging exosome technology; and markets and distributes proprietary exosome isolation systems and related products to hospitals, as well as provides development services for hospitals. In addition, it owns and operates real property. The company has a strategic partnership Weill Cornell Medical College to co-develop technologies and bio-production of chimeric antigen receptor-T Therapy. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.

Receive News & Ratings for Genpact Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genpact and related companies with MarketBeat.com's FREE daily email newsletter.